Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:MIRM NASDAQ:MLTX NASDAQ:MTSR NASDAQ:QURE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMIRMMirum Pharmaceuticals$74.31-2.2%$62.19$36.86▼$78.10$3.73B0.92736,079 shs336,390 shsMLTXMoonLake Immunotherapeutics$52.62-3.1%$53.78$31.42▼$61.87$3.49B1.27575,855 shs864,952 shsMTSRMetsera$35.67-4.2%$35.49$12.30▼$47.40$3.75BN/A1.34 million shs1.61 million shsQUREuniQure$16.49-2.7%$15.28$4.45▼$19.18$929.45M0.14901,117 shs670,611 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMIRMMirum Pharmaceuticals0.00%-2.30%+14.62%+49.73%+77.31%MLTXMoonLake Immunotherapeutics0.00%-11.47%-4.12%+19.02%+13.36%MTSRMetsera0.00%-0.56%+17.72%+21.41%+3,566,999,900.00%QUREuniQure0.00%-8.13%+4.50%+7.50%+201.46%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMIRMMirum Pharmaceuticals$74.31-2.2%$62.19$36.86▼$78.10$3.73B0.92736,079 shs336,390 shsMLTXMoonLake Immunotherapeutics$52.62-3.1%$53.78$31.42▼$61.87$3.49B1.27575,855 shs864,952 shsMTSRMetsera$35.67-4.2%$35.49$12.30▼$47.40$3.75BN/A1.34 million shs1.61 million shsQUREuniQure$16.49-2.7%$15.28$4.45▼$19.18$929.45M0.14901,117 shs670,611 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMIRMMirum Pharmaceuticals0.00%-2.30%+14.62%+49.73%+77.31%MLTXMoonLake Immunotherapeutics0.00%-11.47%-4.12%+19.02%+13.36%MTSRMetsera0.00%-0.56%+17.72%+21.41%+3,566,999,900.00%QUREuniQure0.00%-8.13%+4.50%+7.50%+201.46%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMIRMMirum Pharmaceuticals 3.11Buy$74.440.18% UpsideMLTXMoonLake Immunotherapeutics 2.78Moderate Buy$74.4341.45% UpsideMTSRMetsera 3.14Buy$63.5078.02% UpsideQUREuniQure 3.00Buy$37.45127.13% UpsideCurrent Analyst Ratings BreakdownLatest QURE, MIRM, MLTX, and MTSR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/12/2025MIRMMirum PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$53.00 ➝ $77.009/9/2025MTSRMetseraLeerink PartnrsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy9/9/2025MTSRMetseraLeerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$77.009/8/2025QUREuniQureChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$35.009/5/2025QUREuniQureHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$70.009/3/2025MTSRMetseraCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight8/29/2025QUREuniQureChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$35.008/28/2025MTSRMetseraBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$45.00 ➝ $50.008/14/2025QUREuniQureMizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Outperform$30.008/11/2025MIRMMirum PharmaceuticalsStifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy$89.008/8/2025MIRMMirum PharmaceuticalsEvercore ISISubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$77.00 ➝ $89.00(Data available from 9/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMIRMMirum Pharmaceuticals$429.16M8.70N/AN/A$4.70 per share15.81MLTXMoonLake ImmunotherapeuticsN/AN/AN/AN/A$7.09 per shareN/AMTSRMetseraN/AN/AN/AN/A($2.46) per shareN/AQUREuniQure$27.12M33.36N/AN/A($0.14) per share-117.79Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMIRMMirum Pharmaceuticals-$87.94M-$1.21N/AN/AN/A-13.65%-24.76%-8.50%11/11/2025 (Estimated)MLTXMoonLake Immunotherapeutics-$118.94M-$2.78N/AN/AN/AN/A-40.98%-35.81%11/6/2025 (Estimated)MTSRMetsera-$209.13MN/A0.00∞N/AN/AN/AN/AN/AQUREuniQure-$239.56M-$3.92N/AN/AN/A-1,387.98%-1,010.74%-33.27%11/4/2025 (Estimated)Latest QURE, MIRM, MLTX, and MTSR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025MIRMMirum Pharmaceuticals-$0.31-$0.12+$0.19-$0.12$107.91 million$127.79 million8/5/2025Q2 2025MLTXMoonLake Immunotherapeutics-$0.73-$0.87-$0.14-$0.87N/AN/A7/29/2025Q2 2025QUREuniQure-$0.89-$0.69+$0.20-$0.69$5.00 million$5.26 million7/28/2025Q2 2025MTSRMetseraN/A-$0.66N/A-$0.66N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthMIRMMirum PharmaceuticalsN/AN/AN/AN/AN/AMLTXMoonLake ImmunotherapeuticsN/AN/AN/AN/AN/AMTSRMetseraN/AN/AN/AN/AN/AQUREuniQureN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMIRMMirum Pharmaceuticals1.213.132.97MLTXMoonLake Immunotherapeutics0.2116.6516.65MTSRMetseraN/A5.265.26QUREuniQure1.539.989.98Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMIRMMirum PharmaceuticalsN/AMLTXMoonLake Immunotherapeutics93.85%MTSRMetseraN/AQUREuniQure78.83%Insider OwnershipCompanyInsider OwnershipMIRMMirum Pharmaceuticals14.36%MLTXMoonLake Immunotherapeutics12.02%MTSRMetseraN/AQUREuniQure4.79%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMIRMMirum Pharmaceuticals14050.24 million43.02 millionOptionableMLTXMoonLake Immunotherapeutics264.23 million56.51 millionOptionableMTSRMetsera81105.06 millionN/AN/AQUREuniQure50054.87 million52.24 millionOptionableQURE, MIRM, MLTX, and MTSR HeadlinesRecent News About These CompaniesuniQure (NASDAQ:QURE) Earns "Buy" Rating from Chardan CapitalSeptember 10, 2025 | americanbankingnews.comuniQure's (QURE) Buy Rating Reiterated at HC WainwrightSeptember 8, 2025 | americanbankingnews.comuniQure: Getting Nervous Ahead Of Critical Huntington's Gene Therapy DataSeptember 5, 2025 | seekingalpha.comuniQure Announces Initial AMT-191 Phase I/IIa Data Showing Sustained Increases in α-Gal A Enzyme Activity in Patients with Fabry DiseaseSeptember 5, 2025 | globenewswire.comWall Street Analysts Think uniQure (QURE) Could Surge 142.67%: Read This Before Placing a BetJuly 31, 2025 | zacks.comuniQure N.V. (QURE) Q2 2025 Earnings Call TranscriptJuly 29, 2025 | seekingalpha.comuniQure Narrows Loss in Fiscal Q2July 29, 2025 | fool.comuniQure (QURE) Reports Q2 Loss, Misses Revenue EstimatesJuly 29, 2025 | zacks.comuniQure Announces Second Quarter 2025 Financial Results and Highlights of Recent Company ProgressJuly 29, 2025 | globenewswire.comuniQure to Announce Second Quarter 2025 Financial ResultsJuly 22, 2025 | globenewswire.comuniQure: Price And Value Have Caught UpJune 17, 2025 | seekingalpha.comuniQure Announces Appointment of Kylie O'Keefe as Chief Customer and Strategy OfficerJune 11, 2025 | globenewswire.comuniQure Provides Regulatory Update on AMT-130 for Huntington's DiseaseJune 2, 2025 | globenewswire.com3 Top Genomics Stocks to Add to Your Portfolio in 2025May 21, 2025 | zacks.comWall Street Analysts See a 161.51% Upside in uniQure (QURE): Can the Stock Really Move This High?May 14, 2025 | zacks.comuniQure N.V. (QURE) Q1 2025 Earnings Call TranscriptMay 9, 2025 | seekingalpha.comUniQure (QURE) Reports Q1 Loss, Misses Revenue EstimatesMay 9, 2025 | zacks.comuniQure Announces First Quarter 2025 Financial Results and Highlights of Recent Company ProgressMay 9, 2025 | globenewswire.comuniQure to Announce First Quarter 2025 Financial ResultsMay 5, 2025 | globenewswire.comuniQure (QURE) Moves 38.5% Higher: Will This Strength Last?April 21, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeQURE, MIRM, MLTX, and MTSR Company DescriptionsMirum Pharmaceuticals NASDAQ:MIRM$74.31 -1.68 (-2.21%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$74.31 0.00 (0.00%) As of 09/12/2025 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.MoonLake Immunotherapeutics NASDAQ:MLTX$52.62 -1.68 (-3.09%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$52.66 +0.04 (+0.07%) As of 09/12/2025 07:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.Metsera NASDAQ:MTSR$35.67 -1.58 (-4.24%) As of 09/12/2025 04:00 PM EasternMetsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell in 2022 and is headquartered in New York.uniQure NASDAQ:QURE$16.49 -0.45 (-2.66%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$16.85 +0.36 (+2.18%) As of 09/12/2025 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Football Season Is Here and DraftKings Stock Is Surging RH Stock Slides After Mixed Earnings and Tariff Concerns Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
